Answers are grounded in this paper and cite their sources.
Case report reveals prolonged clotting times in patient treated with cefoperazone/sulbactam, suggesting coagulopathy risk.
This case report described a suspected severe coagulopathy attributed to cefoperazone/sulbactam, and this adverse reaction might be associated with the inhibition of the vitamin K cycle by cefoperazone/sulbactam, leading to vitamin K deficiency within the body. We reported a patient diagnosed with bacterial pneumonia, who received cefoperazone/sulbactam during hospitalization. The patient was administered cefoperazone/sulbactam via intravenous infusion at a dose of 1.5 g every 8 h for a consecutive treatment period of 23 days. On the 26th day, the patient developed a serious adverse reaction characterized by prolonged clotting time. After treatment with vitamin K1, the coagulation parameters significantly improved by the 28th day (prothrombin time decreased by 88.4%, activated partial thromboplastin time decreased by 61.1%, and international normalized ratio decreased by 88.5%). The Naranjo assessment score was 5, suggesting that the patient’s coagulation disorder could be related to the use of cefoperazone/sulbactam. This report highlights that patients at high risk of bleeding should be vigilant about the coagulopathy caused by cefoperazone/sulbactam- and extend the duration of coagulopathy monitoring.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: